Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Rivaroxaban Versus Apixaban for Treatment of Cancer-Associated Venous Thromboembolism: A Head-to-Head Analysis of the United States Cohort of the Observational Study in Cancer-Associated Thrombosis for Rivaroxaban: (H2H-OSCAR-US)

Kimberly Snow Caroti, Khaled Abdelgawwad, George Psaroudakis, Marcela Rivera, Gunnar Brobert, Alexander T Cohen, Alok A Khorana, Cecilia Becattini, Agnes Y. Lee, Anders Ekbom, Marc Carrier, Craig I. Coleman

Blood (2022) 140 (Supplement 1): 1257–1258.

https://doi.org/10.1182/blood-2022-167801

Published: 2022

Journal Articles

Meta-Analysis and Meta-Regression to Assess Four-Factor Prothrombin Complex Concentrate's Ability to Achieve Hemostatic Effectiveness in Patients with Oral Factor Xa Inhibitor-Associated Intracranial Hemorrhage

Kimberly Snow Caroti, Peter Lemere, Craig I. Coleman

Blood (2022) 140 (Supplement 1): 8520–8521.

https://doi.org/10.1182/blood-2022-163584

Published: 2022

Journal Articles

Comparison of Rivaroxaban and Low Molecular Weight Heparin in the Treatment of Cancer-Associated Venous Thromboembolism

Craig I. Coleman, Kimberly Snow Caroti, Khaled Abdelgawwad, George Psaroudakis, Marcela Rivera, Gunnar Brobert, Alexander T. Cohen, Alok A. Khorana, Cecilia Becattini, Agnes Y. Lee, Anders Ekbom, Marc Carrier

Blood (2022) 140 (Supplement 1): 11368–11369.

https://doi.org/10.1182/blood-2022-166949

Published: 2022

Journal Articles

Thromboembolism, Bleeding, and Vascular Death Among Older and Younger Nonvalvular Atrial Fibrillation Patients with Type 2 Diabetes Receiving Rivaroxaban or Warfarin

Craig I. Coleman, Christopher Brescia, Burcu Vardar, Khaled Abdelgawwad, Nitesh Sood

Blood (2021) 138 (Supplement 1): 3234.

https://doi.org/10.1182/blood-2021-151508

Published: 2021

Journal Articles

Patient Characteristics and Temporal Changes in Anticoagulation Treatment Patterns in Patients Diagnosed with Cancer-Associated Thrombosis: An Oscar-US Analysis

Craig I. Coleman, Kimberly Snow Caroti, Khaled Abdelgawwad, George Psaroudakis, Samuel Fatoba, Marcela Rivera, Gunnar Brobert, Christopher Brescia

Blood (2021) 138 (Supplement 1): 2132.

https://doi.org/10.1182/blood-2021-151566

Published: 2021

Journal Articles

Safety and Effectiveness of Rivaroxaban Versus Low Molecular Weight Heparin for Treatment of Cancer-Associated Venous Thrombosis: A SEER-Medicare-Linked Data Analysis

Christine G. Kohn, PharmD, Gary H. Lyman, MD MPH, Nicole M. Kuderer, Thomas J. Bunz, PharmD, PhD, Craig I. Coleman, PharmD

Blood (2019) 134 (Supplement_1): 3673.

https://doi.org/10.1182/blood-2019-128581

Published: 2019

Journal Articles

Impact of Prolonged Anticoagulation with Rivaroxaban on Provoked Venous Thromboembolism Recurrence: The Improve-VTE Study

Craig I. Coleman, PharmD, Alexander G. Turpie, MD, Thomas J. Bunz, PharmD, PhD, Jan Beyer-Westendorf, MD, William L Baker, PharmD

Blood (2018) 132 (Supplement 1): 1241.

https://doi.org/10.1182/blood-2018-99-114133

Published: 2018

Journal Articles

Effectiveness and Safety of Rivaroxaban Vs. Warfarin in Patients with Nonvalvular Atrial Fibrillation and Moderate-to-Severe Chronic Kidney Disease

Craig I. Coleman, PharmD, Brandon K. Martinez, PharmD, Alexander G. G. Turpie, MD, Nitesh Sood, MD, Thomas J. Bunz, PharmD, PhD, Reinhold Kreutz, PhD

Blood (2017) 130 (Supplement 1): 2393.

https://doi.org/10.1182/blood.V130.Suppl_1.2393.2393

Published: 2017

Journal Articles

Effectiveness and Safety of Rivaroxaban Versus Warfarin for Treatment of Venous Thromboembolism in Patients with Known Primary Hypercoagulable States

Craig I. Coleman, PharmD, Alexander G. G. Turpie, MD, Thomas J. Bunz, PharmD, PhD, Jan Beyer-Westendorf, MD

Blood (2017) 130 (Supplement 1): 1113.

https://doi.org/10.1182/blood.V130.Suppl_1.1113.1113

Published: 2017

Journal Articles

A Meta-Analysis of the Prognostic Accuracy of Clinical Prediction Rules for Post-Pulmonary Embolism Mortality in Patients with Cancer

Jonathan Caranfa, PharmD, Christine G. Kohn, BS, PharmD, Gary H. Lyman, MD MPH, FRCP, Nicole M. Kuderer, MD, Catherine Stirbis, BS, Mark Wysocki, PharmD, Craig I. Coleman, PharmD, Erin R Weeda, PharmD, Elaine Nguyen, PharmD

Blood (2017) 130 (Supplement 1): 2105.

https://doi.org/10.1182/blood.V130.Suppl_1.2105.2105

Published: 2017

Journal Articles

Effectiveness and Safety of Rivaroxaban in Patients with Cancer-Associated Venous Thromboembolism

Christine G. Kohn, BS, PharmD, Gary H. Lyman, MD MPH, FRCP, Jan Beyer-Westendorf, MD, Alex C. Spyropoulos, MD, Thomas J. Bunz, PharmD, PhD, Craig I. Coleman, PharmD

Blood (2017) 130 (Supplement 1): 3717.

https://doi.org/10.1182/blood.V130.Suppl_1.3717.3717

Published: 2017

Journal Articles

External Validation of a Clinical and Claims-Based Approach for Predicting 90-Day Post-Pulmonary Embolism Outcomes Among US Veterans

Neela K Kumar, MSPH, Erin R Weeda, PharmD, Philip S Wells, MD, Frank Peacock, MD, Gregory J Fermann, MD, Li Wang, MA, PhD MBA, Onur Baser, MS, PhD, Jeff Schein, DrPH, MPH, Crivera Crivera, PharmD, MPH, Craig I Coleman, PharmD, Christine G Kohn, PharmD

Blood (2016) 128 (22): 533.

https://doi.org/10.1182/blood.V128.22.533.533

Published: 2016

Journal Articles

External Validation of Generic and Cancer-Specific Risk Stratification Criteria for Predicting 30-Day Mortality in Patients Presenting with Pulmonary Embolism and Active Cancer

Jonathan T Caranfa, PharmD, Erin R Weeda, PharmD, Craig I Coleman, PharmD, Simon B. Zeichner, D.O., Christine G Kohn, PharmD

Blood (2016) 128 (22): 4730.

https://doi.org/10.1182/blood.V128.22.4730.4730

Published: 2016

Journal Articles

Reduced Costs and Length-of-Stay Associated with Rivaroxaban As Compared to Parenteral Bridging and Warfarin in Pulmonary Embolism Patients Managed in Observation Status

Christine G Kohn, PharmD, Erin R Weeda, PharmD, W Frank Peacock, MD FACEP, Gregory J Fermann, MD, Christopher W. Baugh, MD MBA, Philip S Wells, MD FRCPC, MSc, Veronica Ashton, MPH, Concetta Crivera, PharmD, MPH, Peter Wildgoose, PhD, Jeff Schein, DrPH, MPH, Craig I Coleman, PharmD

Blood (2016) 128 (22): 2337.

https://doi.org/10.1182/blood.V128.22.2337.2337

Published: 2016

Journal Articles

Does the Timing of Vital Sign Measurements Affect Simplified Pulmonary Embolism Severity Index (sPESI) Risk Determination?

Christine G Kohn, PharmD, Heather Rozjabek, MPH, Gregory J Fermann, MD, W Frank Peacock, MD FACEP, Concetta Crivera, Jeff Schein, Craig I Coleman, PharmD

Blood (2015) 126 (23): 2058.

https://doi.org/10.1182/blood.V126.23.2058.2058

Published: 2015

Journal Articles

Validation of the Inhospital Mortality for Pulmonary Embolism Using Claims Data (IMPACT) Prediction Rule within an All-Payer Inpatient Administrative Claims Database

Craig I Coleman, PharmD, Christine G Kohn, PharmD, Concetta Crivera, Jeff Schein, W Frank Peacock, MD FACEP

Blood (2015) 126 (23): 747.

https://doi.org/10.1182/blood.V126.23.747.747

Published: 2015

Journal Articles

Pulmonary Embolism Begets Pulmonary Embolism?: A Meta-Analysis Depicting the Type of Recurrence Following an Index Pulmonary Embolism

Craig I Coleman, PharmD, Christine G Kohn, PharmD, Dhaval Patel, BS

Blood (2014) 124 (21): 4832.

https://doi.org/10.1182/blood.V124.21.4832.4832

Published: 2014

NARROW

Rivaroxaban Versus Apixaban for Treatment of Cancer-Associated Venous Thromboembolism: A Head-to-Head Analysis of the United States Cohort of the Observational Study in Cancer-Associated Thrombosis for Rivaroxaban: (H2H-OSCAR-US)

Meta-Analysis and Meta-Regression to Assess Four-Factor Prothrombin Complex Concentrate's Ability to Achieve Hemostatic Effectiveness in Patients with Oral Factor Xa Inhibitor-Associated Intracranial Hemorrhage

Comparison of Rivaroxaban and Low Molecular Weight Heparin in the Treatment of Cancer-Associated Venous Thromboembolism

Thromboembolism, Bleeding, and Vascular Death Among Older and Younger Nonvalvular Atrial Fibrillation Patients with Type 2 Diabetes Receiving Rivaroxaban or Warfarin

Patient Characteristics and Temporal Changes in Anticoagulation Treatment Patterns in Patients Diagnosed with Cancer-Associated Thrombosis: An Oscar-US Analysis

Safety and Effectiveness of Rivaroxaban Versus Low Molecular Weight Heparin for Treatment of Cancer-Associated Venous Thrombosis: A SEER-Medicare-Linked Data Analysis

Impact of Prolonged Anticoagulation with Rivaroxaban on Provoked Venous Thromboembolism Recurrence: The Improve-VTE Study

Effectiveness and Safety of Rivaroxaban Vs. Warfarin in Patients with Nonvalvular Atrial Fibrillation and Moderate-to-Severe Chronic Kidney Disease

Effectiveness and Safety of Rivaroxaban Versus Warfarin for Treatment of Venous Thromboembolism in Patients with Known Primary Hypercoagulable States

A Meta-Analysis of the Prognostic Accuracy of Clinical Prediction Rules for Post-Pulmonary Embolism Mortality in Patients with Cancer

Effectiveness and Safety of Rivaroxaban in Patients with Cancer-Associated Venous Thromboembolism

External Validation of a Clinical and Claims-Based Approach for Predicting 90-Day Post-Pulmonary Embolism Outcomes Among US Veterans

External Validation of Generic and Cancer-Specific Risk Stratification Criteria for Predicting 30-Day Mortality in Patients Presenting with Pulmonary Embolism and Active Cancer

Reduced Costs and Length-of-Stay Associated with Rivaroxaban As Compared to Parenteral Bridging and Warfarin in Pulmonary Embolism Patients Managed in Observation Status

Does the Timing of Vital Sign Measurements Affect Simplified Pulmonary Embolism Severity Index (sPESI) Risk Determination?

Validation of the Inhospital Mortality for Pulmonary Embolism Using Claims Data (IMPACT) Prediction Rule within an All-Payer Inpatient Administrative Claims Database

Pulmonary Embolism Begets Pulmonary Embolism?: A Meta-Analysis Depicting the Type of Recurrence Following an Index Pulmonary Embolism

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only